Pemvidutide
About
About Pemvidutide
Pemvidutide is a GLP-1/glucagon dual receptor agonist being developed by Altimmune, showing Phase II weight loss of approximately 15% over 48 weeks with a notable advantage of preserving lean muscle mass — a key differentiator versus pure GLP-1 agents. Its glucagon component increases energy expenditure and fat oxidation while the GLP-1 component manages appetite and glucose. Early data suggests a favorable body composition profile compared to semaglutide.
Science
Mechanism of Action
Balanced co-agonism at GLP-1 receptors (appetite suppression, insulin secretion) and glucagon receptors (thermogenesis, fat oxidation, hepatic lipid metabolism) with a ratio designed to maximize fat loss while minimizing lean tissue catabolism.
Dosing
Typical Protocol
1.2–2.4 mg subcutaneous injection once weekly; Phase II dose range.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Regulatory
Legal Status in 2026
This compound occupies a regulatory grey area in 2026. It is neither explicitly FDA-approved nor clearly illegal for personal use, but it lacks formal clinical approval and may not be legally sold for human use in all contexts. Proceed with caution: source quality is variable, and regulatory status can change. Always consult a physician.
Evidence
Evidence Tier
Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard — effects have been measured in controlled conditions and results are peer-reviewed and reproducible.
Find a Verified Provider
See which Vial-verified providers offer Pemvidutide — with trust scores, legal credentials, and pricing transparency.